6,887 Becton, Dickinson and Company $BDX Shares Purchased by Sumitomo Mitsui DS Asset Management Company Ltd

Sumitomo Mitsui DS Asset Management Company Ltd boosted its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 18.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 43,413 shares of the medical instruments supplier’s stock after acquiring an additional 6,887 shares during the quarter. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Becton, Dickinson and Company were worth $7,771,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Brown Lisle Cummings Inc. increased its holdings in shares of Becton, Dickinson and Company by 9.2% in the 2nd quarter. Brown Lisle Cummings Inc. now owns 644 shares of the medical instruments supplier’s stock valued at $97,000 after purchasing an additional 54 shares during the period. Pension & Wealth Management Advisors Inc. lifted its position in shares of Becton, Dickinson and Company by 12.3% in the third quarter. Pension & Wealth Management Advisors Inc. now owns 510 shares of the medical instruments supplier’s stock worth $94,000 after purchasing an additional 56 shares in the last quarter. Elevation Point Wealth Partners LLC boosted its holdings in shares of Becton, Dickinson and Company by 3.7% during the second quarter. Elevation Point Wealth Partners LLC now owns 1,692 shares of the medical instruments supplier’s stock worth $256,000 after purchasing an additional 60 shares during the period. Private Harbour Investment Management & Counsel LLC boosted its holdings in shares of Becton, Dickinson and Company by 1.1% during the second quarter. Private Harbour Investment Management & Counsel LLC now owns 5,511 shares of the medical instruments supplier’s stock worth $834,000 after purchasing an additional 62 shares during the period. Finally, NorthRock Partners LLC grew its position in Becton, Dickinson and Company by 2.0% during the second quarter. NorthRock Partners LLC now owns 3,295 shares of the medical instruments supplier’s stock valued at $499,000 after purchasing an additional 65 shares in the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have weighed in on BDX. Bank of America upped their price objective on shares of Becton, Dickinson and Company from $185.00 to $200.00 and gave the company a “neutral” rating in a research note on Monday, August 31st. Weiss Ratings raised shares of Becton, Dickinson and Company from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, September 28th. Wolfe Research initiated coverage on shares of Becton, Dickinson and Company in a research note on Tuesday. They set an “outperform” rating for the company. UBS Group began coverage on shares of Becton, Dickinson and Company in a report on Tuesday, July 28th. They set a “buy” rating and a $190.00 price target on the stock. Finally, Royal Bank Of Canada upped their price target on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the stock a “sector perform” rating in a research note on Thursday, August 13th. Eight equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Becton, Dickinson and Company currently has an average rating of “Hold” and a consensus target price of $185.07.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, CEO Thomas Polen, Jr. sold 4,152 shares of the business’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $185.00, for a total value of $768,120.00. Following the completion of the sale, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at $20,380,155. The trade was a 3.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total transaction of $440,887.92. Following the transaction, the executive vice president owned 14,856 shares in the company, valued at approximately $2,686,559.04. This trade represents a 14.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 6,906 shares of company stock worth $1,265,855 over the last ninety days. 0.40% of the stock is currently owned by insiders.

Becton, Dickinson and Company Stock Up 0.3%

BDX opened at $194.29 on Thursday. The company has a market capitalization of $53.53 billion, a PE ratio of 58.52, a price-to-earnings-growth ratio of 13.07 and a beta of 0.21. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $195.99. The business has a 50-day moving average of $184.73 and a 200-day moving average of $164.54.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, beating the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%. The business had revenue of $4.98 billion during the quarter, compared to analysts’ expectations of $4.89 billion. During the same quarter in the previous year, the business posted $3.68 EPS. The firm’s quarterly revenue was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Equities research analysts forecast that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th were paid a $1.05 dividend. The ex-dividend date was Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a yield of 2.2%. Becton, Dickinson and Company’s payout ratio is 126.51%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.